Bristol Myers Squibb announced positive data from two separate Phase III clinical trials of the company’s checkpoint inhibitor Opdivo (nivolumab).
Top 200 Medicines Annual Report: Climbing Mount Humira
Analysts, August 2020, Autoimmune Diseases, Biologics, Blockbusters, Checkpoint Inhibitors, Chemotherapy, FDA, Healthcare Physicians, Human Anti-CD38 Monoclonal Antibody, Immuno-oncology, Issue Archives, Med Ad News, Metastatic squamous cell carcinoma of the esophagus, Multiple myeloma, Oncology, PD-1/PD-L1 inhibitors, Therapeutics, Top 200 MedicinesWhile Humira remains the best-selling prescription product worldwide, Keytruda has risen to the No. 2 global rank and is on track to eventually claim the top spot.
Top 200 Medicines Annual Report 2019: The king of medicines
Ankylosing Spondylitits, August 2019, Autoimmune Diseases, Biologics, Biosimilars, Blockbusters, Cervical Cancer, Classical Hodgkin Lymphoma, Crohn's Disease, Esophageal Cancer, Forecasts, Gastric Cancer, Head & Neck Cancer, Hepatocellular Carcinoma, Hidradenitis suppurativa, Issue Archives, Juvenile Idiopathic Arthritis, Market exclusivity, Melanoma, Merkel cell carcinoma, Metastatic Urothelial Carcinoma (mUC), Microsatellite instability-high (MSI-H) cancer, Monoclonal Antibodies, Non-Small Cell Lung Cancer (NSCLC), Plaque Psoriasis, Primary lediastinal large B-cell lymphoma, Product Launches, Psoriatic Arthritis, Renal Cell Carcinoma (RCC), Rheumatoid Arthritis, Therapeutics, Top 200 Medicines, Ulcerative Colitis, UveitisHumira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
The U.S. Food and Drug Administration approved the anti-PD-1 therapy Keytruda as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.
Merck’s Keytruda Cuts Death Risk by 31 Percent in Esophageal Cancer
Blockbusters, Chemotherapy, Clinical Trials, Esophageal Cancer, FDA/Regulatory, Gastric Cancer, Gastrointestinal cancer, Hepatocellular Carcinoma, J.P. Morgan Healthcare Conference, PD-1 Inhibitors, R&D, Squamous Cell Carcinoma, TherapeuticsMerck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
Investing Into R&D Pays off for Some of Biotech’s Biggest Companies
Acute Myeloid Leukemia (AML), Atrial Fibrillation, Big Pharma, Biotech, Blood Cancers, Cancer, Chemotherapy, Clinical Trials, Ebola Virus, Esophageal Cancer, FDA, Hepatocellular Carcinoma, Immunohistochemistry (IHC) Test, Infantile fibrosarcoma, Juvenile breast cancer, R&D, Tropomyosin Receptor Kinase (TRK) proteinsPwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.
Merck & Co.’s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract.
Lumicell Inc. provided an update on the company’s development strategy for its LUM system pipeline including plans to initiate its pivotal trial in breast cancer as well as expansion of its clinical studies in four other solid tumor cancers.